{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T08:49:16Z","timestamp":1785746956517,"version":"3.56.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We assessed pGF in 2497 AML patients undergoing HSCT from 8-10\/10 HLA-matched UD with PTCy. pGF was defined as failure to achieve an ANC\u2009\u2265\u20090.5\u2009\u00d7\u200910\n                    <jats:sup>9<\/jats:sup>\n                    \/L by day +30 after HSCT. The day +30 cumulative incidence of ANC was 92.6% (95%CI: 91.5\u201393.6), and the incidence of death without ANC recovery was 1.8% (95% CI: 1.3%\u20132.3%), corresponding to 141 (5.6%) patients not achieving an ANC\u2009\u2265\u20090.5\u2009\u00d7\u200910\n                    <jats:sup>9<\/jats:sup>\n                    \/L by day +30. PB was the graft source in 89.4% of the patients, and 56% received reduced-intensity conditioning. 21 patients underwent a second HSCT (15 in the absence of ANC recovery and 6 after ANC recovery). 1-y NRM and RI post-pGF were 22.1% and 22.4%, respectively. 1-y LFS and OS post-pGF were 59% and 55.5%, respectively. ANC recovery evaluated as a time-dependent covariate, KPS\u2009\u2265\u200990, and being in CR at the time of HSCT were associated with improved OS. In conclusion, the incidence of pGF post-unrelated HSCT with PTCy was 5.6%. Of the patients who failed to engraft by day +30, 70.9% did so by day +60. A second transplant can save some of the patients with pGF.\n                  <\/jats:p>","DOI":"10.1038\/s41409-025-02726-8","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T11:41:03Z","timestamp":1760787663000},"page":"51-58","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Outcomes of primary graft failure in acute myeloid leukemia patients following unrelated transplantation with post-transplant cyclophosphamide: a study from the ALWP\/EBMT"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0763-1265","authenticated-orcid":false,"given":"Arnon","family":"Nagler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9102-4427","authenticated-orcid":false,"given":"Jacques-Emmanuel","family":"Galimard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9985-1205","authenticated-orcid":false,"given":"Sarah","family":"Kayser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9589-4136","authenticated-orcid":false,"given":"Alexander","family":"Kulagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5684-9447","authenticated-orcid":false,"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Parovichnikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2372-1663","authenticated-orcid":false,"given":"Jurjen","family":"Versluis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maija","family":"It\u00e4la-Remes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goda","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5143-4042","authenticated-orcid":false,"given":"Rodrigo","family":"Martino Bufarull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2426-3465","authenticated-orcid":false,"given":"Simona","family":"Sica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieke W. H.","family":"Roeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7470-7346","authenticated-orcid":false,"given":"Peter","family":"von dem Borne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7171-4997","authenticated-orcid":false,"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6934-4619","authenticated-orcid":false,"given":"Jaime","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0873-0123","authenticated-orcid":false,"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,18]]},"reference":[{"key":"2726_CR1","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","volume":"388","author":"J Bola\u00f1os-Meade","year":"2023","unstructured":"Bola\u00f1os-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388:2338\u201348.","journal-title":"N Engl J Med"},{"key":"2726_CR2","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1182\/bloodadvances.2021005847","volume":"6","author":"AEC Broers","year":"2022","unstructured":"Broers AEC, de Jong CN, Bakunina K, Hazenberg MD, van Marwijk Kooy M, et al. Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial. Blood Adv. 2022;6:3378\u201385.","journal-title":"Blood Adv"},{"key":"2726_CR3","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1182\/blood.2019000487","volume":"134","author":"G Battipaglia","year":"2019","unstructured":"Battipaglia G, Labopin M, Kr\u00f6ger N, Vitek A, Afanasyev B, Hilgendorf I, et al. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood. 2019;134:892\u20139.","journal-title":"Blood"},{"key":"2726_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13045-020-00923-0","volume":"13","author":"E Brissot","year":"2020","unstructured":"Brissot E, Labopin M, Moiseev I, Cornelissen JJ, Meijer E, Van Gorkom G, et al. Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10\/10 HLA-matched unrelated donors. J Hematol Oncol. 2020;13:87.","journal-title":"J Hematol Oncol"},{"key":"2726_CR5","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/s41409-024-02284-5","volume":"59","author":"A Nagler","year":"2024","unstructured":"Nagler A, Labopin M, Swoboda R, Schroeder T, Hamladji RM, Griskevicius L, et al. Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis after allogeneic stem cell transplantation. Bone Marrow Transpl. 2024;59:1012\u201321.","journal-title":"Bone Marrow Transpl"},{"key":"2726_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01032-8","volume":"14","author":"O Penack","year":"2024","unstructured":"Penack O, Abouqateb M, Peczynski C, Boreland W, G\u00fclbas Z, Gedde-Dahl T, et al. PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation. Blood Cancer J. 2024;14:45.","journal-title":"Blood Cancer J"},{"key":"2726_CR7","doi-asserted-by":"crossref","unstructured":"Penack O, Abouqateb M, Peczynski C, Boreland W, Kr\u00f6ger N, Stelljes M, et al. ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation? Leukemia. 2024;38:1156\u201363","DOI":"10.1038\/s41375-024-02225-7"},{"key":"2726_CR8","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jtct.2022.05.012","volume":"28","author":"D Ngo","year":"2022","unstructured":"Ngo D, Samuels D, Chen J, Koller PB, Al Malki MM. A clinical review of the different strategies to minimize hemorrhagic cystitis associated with the use of post-transplantation cyclophosphamide in an allogeneic transplant. Transplant Cell Ther. 2022;28:349\u201354.","journal-title":"Transplant Cell Ther"},{"key":"2726_CR9","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jaccao.2021.02.011","volume":"3","author":"R Dul\u00e9ry","year":"2021","unstructured":"Dul\u00e9ry R, Mohty R, Labopin M, Sestili S, Malard F, Brissot E, et al. Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation. JACC Cardio Oncol. 2021;3:250\u20139.","journal-title":"JACC Cardio Oncol"},{"key":"2726_CR10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1182\/bloodadvances.2020003005","volume":"5","author":"B Rambaldi","year":"2021","unstructured":"Rambaldi B, Kim HT, Reynolds C, Chamling Rai S, Arihara Y, et al. Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. Blood Adv. 2021;5:352\u20135364.","journal-title":"Blood Adv"},{"key":"2726_CR11","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41409-020-01092-x","volume":"56","author":"GC Irene","year":"2021","unstructured":"Irene GC, Albert E, Anna BV, Rahinatu A, Silvana N, Silvana S, et al. Patterns of infection and infection-related mortality in patients receiving post-transplant high-dose cyclophosphamide as graft-versus-host-disease prophylaxis: impact of HLA donor matching. Bone Marrow Transpl. 2021;56:818\u201327.","journal-title":"Bone Marrow Transpl"},{"key":"2726_CR12","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/bjh.13977","volume":"173","author":"RS Mehta","year":"2016","unstructured":"Mehta RS, Saliba RM, Chen J, Rondon G, Hammerstrom AE, Alousi A, et al. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. Br J Haematol. 2016;173:444\u201355.","journal-title":"Br J Haematol"},{"key":"2726_CR13","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41409-023-02159-1","volume":"59","author":"MQ Salas","year":"2024","unstructured":"Salas MQ, Eikema DJ, Koster L, Maertens J, Passweg J, Finke J, et al. Impact of post-transplant cyclophosphamide (PTCy)-based prophylaxis in matched sibling donor allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transpl. 2024;59:479\u201388.","journal-title":"Bone Marrow Transpl"},{"key":"2726_CR14","doi-asserted-by":"crossref","unstructured":"Battipaglia G, Labopin M, Hamladji RM, Blaise D, Chevallier P, Brissot E, et al. Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: a retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2021;127:209\u201318","DOI":"10.1002\/cncr.33255"},{"key":"2726_CR15","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.jtct.2021.06.018","volume":"27","author":"D Modi","year":"2021","unstructured":"Modi D, Kondrat K, Kim S, Deol A, Ayash L, Ratanatharathorn V, et al. Post-transplant cyclophosphamide versus thymoglobulin in HLA-mismatched unrelated donor transplant for acute myelogenous leukemia and myelodysplastic syndrome. Transplant Cell Ther. 2021;27:760\u20137.","journal-title":"Transplant Cell Ther"},{"key":"2726_CR16","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1002\/ajh.27383","volume":"99","author":"A Nagler","year":"2024","unstructured":"Nagler A, Ngoya M, Galimard JE, Labopin M, Blau IW, Kr\u00f6ger N, et al. Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide versus conventional anti-graft versus host disease prophylaxis in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2024;99:1732\u201345.","journal-title":"Am J Hematol"},{"key":"2726_CR17","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jtct.2021.04.007","volume":"27","author":"MA Kharfan-Dabaja","year":"2021","unstructured":"Kharfan-Dabaja MA, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R, et al. Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a Report on behalf of the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2021;27:642\u20139.","journal-title":"Transplant Cell Ther"},{"key":"2726_CR18","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/bmt.2012.239","volume":"48","author":"R Olsson","year":"2013","unstructured":"Olsson R, Remberger M, Schaffer M, Berggren DM, Svahn BM, Mattsson J, et al. Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transpl. 2013;48:537\u201343.","journal-title":"Bone Marrow Transpl"},{"key":"2726_CR19","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/16078454.2022.2042064","volume":"27","author":"J Chen","year":"2022","unstructured":"Chen J, Pang A, Zhao Y, Liu L, Ma R, Wei J, et al. Primary graft failure following allogeneic hematopoietic stem cell transplantation: risk factors, treatment, and outcomes. Hematology. 2022;27:293\u20139.","journal-title":"Hematology"},{"key":"2726_CR20","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2021.36.e151","volume":"36","author":"JH Park","year":"2021","unstructured":"Park JH, Lee JH, Lee JH, Park HS, Choi EJ, Kang YA, et al. Incidence, management, and prognosis of graft failure and autologous reconstitution after allogeneic hematopoietic stem cell transplantation. J Korean Med Sci. 2021;36:e151.","journal-title":"J Korean Med Sci"},{"key":"2726_CR21","doi-asserted-by":"publisher","first-page":"4096","DOI":"10.1182\/blood.V96.13.4096","volume":"96","author":"SM Davies","year":"2000","unstructured":"Davies SM, Kollman C, Anasetti C, Antin JH, Gajewski J, Casper JT, et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the National Marrow Donor Program. Blood. 2000;96:4096\u2013102.","journal-title":"Blood"},{"key":"2726_CR22","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199811263392201","volume":"339","author":"P Rubinstein","year":"1998","unstructured":"Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio AR, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med. 1998;339:1565\u201377.","journal-title":"N Engl J Med"},{"key":"2726_CR23","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1111\/vox.13368","volume":"117","author":"JH Chakrabarty","year":"2022","unstructured":"Chakrabarty JH, Glover J, Schmidt S, Phan M, Bycko M, Duong Q, et al. Incidence and risk factors for graft failure in the modern era of cord blood transplantation. Vox Sang. 2022;117:1405\u201310.","journal-title":"Vox Sang"},{"key":"2726_CR24","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41409-017-0062-8","volume":"53","author":"SO Ciurea","year":"2018","unstructured":"Ciurea SO, Cao K, Fernandez-Vina M, Kongtim P, Malki MA, Fuchs E, et al. The European Society for Blood and Marrow Transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation. Bone Marrow Transpl. 2018;53:521\u201334.","journal-title":"Bone Marrow Transpl"},{"key":"2726_CR25","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/ajh.26834","volume":"98","author":"GS Guru Murthy","year":"2023","unstructured":"Guru Murthy GS, Logan BR, Bo-Subait S, Beitinjaneh A, Devine S, Farhadfar N, et al. Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia. Am J Hematol. 2023;98:608\u201319.","journal-title":"Am J Hematol"},{"key":"2726_CR26","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/bmt.2015.351","volume":"51","author":"T Cluzeau","year":"2016","unstructured":"Cluzeau T, Lambert J, Raus N, Dessaux K, Absi L, Delbos F, et al. Risk factors and outcome of graft failure after HLA-matched and mismatched unrelated donor hematopoietic stem cell transplantation: a study on behalf of SFGM-TC and SFHI. Bone Marrow Transpl. 2016;51:687\u201391.","journal-title":"Bone Marrow Transpl"},{"key":"2726_CR27","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3109\/10428194.2014.930849","volume":"56","author":"C Ferr\u00e0","year":"2015","unstructured":"Ferr\u00e0 C, Sanz J, D\u00edaz-P\u00e9rez MA, Morgades M, Gayoso J, Cabrera JR, et al. Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients. Leuk Lymphoma. 2015;56:656\u201362.","journal-title":"Leuk Lymphoma"},{"key":"2726_CR28","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1056\/NEJM199810223391702","volume":"339","author":"F Aversa","year":"1998","unstructured":"Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339:1186\u201393.","journal-title":"N Engl J Med"},{"key":"2726_CR29","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0171-2985(96)80033-7","volume":"195","author":"H Mayumi","year":"1996","unstructured":"Mayumi H, Umesue M, Nomoto K. Cyclophosphamide-induced immunological tolerance: an overview. Immunobiology. 1996;195:129\u201339.","journal-title":"Immunobiology"},{"key":"2726_CR30","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1182\/bloodadvances.2017009423","volume":"1","author":"F Aversa","year":"2017","unstructured":"Aversa F, Lustig EB, Geva NO, Prezioso L, Bonomini S, Manfra I, et al. Immune tolerance induction by nonmyeloablative haploidentical HSCT combining T-cell depletion and posttransplant cyclophosphamide. Blood Adv. 2017;1:2166\u201375.","journal-title":"Blood Adv"},{"key":"2726_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2023.101808","volume":"77","author":"FW Hoff","year":"2023","unstructured":"Hoff FW, Chung SS, Patel PA, Permnath N, Khatib J, Ovcina MT, et al. Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies: a single-center experience. Transpl Immunol. 2023;77:101808.","journal-title":"Transpl Immunol"},{"key":"2726_CR32","doi-asserted-by":"publisher","first-page":"313.e1","DOI":"10.1016\/j.jtct.2023.01.009","volume":"29","author":"J Marco- Ayala","year":"2023","unstructured":"Marco- Ayala J, Sanz JM, Segu\u00ed IG, Balaguer-Rosello A, Montoro J, Guerreiro M, et al. Impact of post-transplantation cyclophosphamide on transfusion requirements in HLA-matched sibling peripheral blood stem cell transplantation. Transplant Cell Ther. 2023;29:313.e1\u2013313.e.","journal-title":"Transplant Cell Ther"},{"key":"2726_CR33","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L, O\u2019Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, post-transplantation cyclophosphamide. Biol Blood Marrow Transpl. 2008;14:641\u201350.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2726_CR34","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1038\/s41409-021-01248-3","volume":"56","author":"A Ruggeri","year":"2021","unstructured":"Ruggeri A, Labopin M, Angelucci E, Blaise D, Ciceri F, Koc Y, et al. Prognostic factors for neutrophil engraftment after haploidentical cell transplantation with PT-Cy in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMT. Bone Marrow Transpl. 2021;56:1842\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"2726_CR35","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628\u201333.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2726_CR36","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transpl. 1995;15:825\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"2726_CR37","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","volume":"69","author":"HM Shulman","year":"1980","unstructured":"Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204\u201317.","journal-title":"Am J Med"},{"key":"2726_CR38","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2991\/chi.d.191207.001","volume":"2","author":"AS Kanate","year":"2019","unstructured":"Kanate AS, Nagler A, Savani B. Summary of scientific and statistical methods, study endpoints, and definitions for observational and registry-based studies in hematopoietic cell transplantation. Clin Hematol Int. 2019;2:2\u20134.","journal-title":"Clin Hematol Int"},{"key":"2726_CR39","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing; 2020.https:\/\/www.R-project.org\/"},{"key":"2726_CR40","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/s41409-023-02012-5","volume":"58","author":"A Nagler","year":"2023","unstructured":"Nagler A, Labopin M, Swoboda R, Kulagin A, Velardi A, Sanz J, et al. Long-term outcome of second allogeneic hematopoietic stem cell transplantation (HSCT2) for primary graft failure in patients with acute leukemia in remission: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transpl. 2023;58:1008\u201316.","journal-title":"Bone Marrow Transpl"},{"key":"2726_CR41","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.bbmt.2010.02.013","volume":"16","author":"J Schriber","year":"2010","unstructured":"Schriber J, Agovi MA, Ho V, Ballen KK, Bacigalupo A, Lazarus HM, et al. Second unrelated donor hematopoietic cell transplantation for primary graft failure. Biol Blood Marrow Transpl. 2010;16:1099\u2013106.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2726_CR42","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.1016\/S2352-3026(19)30158-9","volume":"6","author":"R Shouval","year":"2019","unstructured":"Shouval R, Fein JA, Labopin M, Kr\u00f6ger N, Duarte RF, Bader P, et al. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. Lancet Haematol. 2019;6:e573\u2013584.","journal-title":"Lancet Haematol"},{"key":"2726_CR43","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/joim.12854","volume":"285","author":"J Canaani","year":"2019","unstructured":"Canaani J, Beohou E, Labopin M, Ghavamzadeh A, Beelen D, Hamladji RM, et al. Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP\/EBMT analysis. J Intern Med. 2019;285:407\u201318.","journal-title":"J Intern Med"},{"key":"2726_CR44","doi-asserted-by":"publisher","first-page":"6283","DOI":"10.1182\/bloodadvances.2020003418","volume":"4","author":"O Penack","year":"2020","unstructured":"Penack O, Peczynski C, Mohty M, Yakoub-Agha I, Styczynski J, Montoto S, et al. How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT. Blood Adv. 2020;4:6283\u201390.","journal-title":"Blood Adv"},{"key":"2726_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01060-4","volume":"14","author":"AK Schm\u00e4lter","year":"2024","unstructured":"Schm\u00e4lter AK, Ngoya M, Galimard JE, Bazarbachi A, Finke J, Kr\u00f6ger N, et al. Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients. Blood Cancer J. 2024;14:76.","journal-title":"Blood Cancer J"},{"key":"2726_CR46","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1172\/JCI124218","volume":"129","author":"LP Wachsmuth","year":"2019","unstructured":"Wachsmuth LP, Patterson MT, Eckhaus MA, Venzon DJ, Gress RE, Kanakry CG. Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T-cell dysfunction and suppression. J Clin Invest. 2019;129:2357\u201373.","journal-title":"J Clin Invest"},{"key":"2726_CR47","doi-asserted-by":"publisher","first-page":"211ra157","DOI":"10.1126\/scitranslmed.3006960","volume":"5","author":"CG Kanakry","year":"2013","unstructured":"Kanakry CG, Ganguly S, Zahurak M, Bola\u00f1os-Meade J, Thoburn C, Perkins B, et al. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to post-transplantation cyclophosphamide. Sci Transl Med. 2013;5:211ra157.","journal-title":"Sci Transl Med"},{"key":"2726_CR48","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1182\/blood.2021013054","volume":"139","author":"SR McCurdy","year":"2022","unstructured":"McCurdy SR, Radojcic V, Tsai HL, Vulic A, Thompson E, Ivcevic S, et al. Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning. Blood. 2022;139:608\u201323.","journal-title":"Blood"},{"key":"2726_CR49","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13045-022-01287-3","volume":"15","author":"C Zhao","year":"2022","unstructured":"Zhao C, Bartock M, Jia B, Shah N, Claxton DF, Wirk B, et al. Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant. J Hematol Oncol. 2022;15:64.","journal-title":"J Hematol Oncol"},{"key":"2726_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.46989\/001c.94952","volume":"6","author":"J Sawyer","year":"2024","unstructured":"Sawyer J, Elliott T, Orton L, Sowell H, Gatwood K, Shultes K. Prevention and management of acute toxicities from conditioning regimens during hematopoietic stem cell transplantation. Clin Hematol Int. 2024;6:1\u201310.","journal-title":"Clin Hematol Int"},{"key":"2726_CR51","doi-asserted-by":"publisher","first-page":"174.e1","DOI":"10.1016\/j.jtct.2024.12.021","volume":"31","author":"CL Hickey","year":"2025","unstructured":"Hickey CL, Zhang MJ, Allbee-Johnson M, Romee R, Majhail NS, Malki MMA, et al. Donor type does not impact late graft failure following reduced-intensity allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis. Transplant Cell Ther. 2025;31:174.e1\u201312.","journal-title":"Transplant Cell Ther"},{"key":"2726_CR52","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1038\/s41409-020-01183-9","volume":"56","author":"S Giammarco","year":"2021","unstructured":"Giammarco S, Raiola AM, Di Grazia C, Bregante S, Gualandi F, Varaldo R, et al. Second haploidentical stem cell transplantation for primary graft failure. Bone Marrow Transpl. 2021;56:1291\u20136.","journal-title":"Bone Marrow Transpl"},{"key":"2726_CR53","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1038\/s41409-020-0821-9","volume":"55","author":"K Harada","year":"2020","unstructured":"Harada K, Fuji S, Seo S, Kanda J, Ueki T, Kimura F, et al. Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl. 2020;55:1784\u201395.","journal-title":"Bone Marrow Transpl"},{"key":"2726_CR54","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.jtct.2024.03.018","volume":"30","author":"JR Mata","year":"2024","unstructured":"Mata JR, Zahurak M, Rosen N, DeZern AE, Jones RJ, Ambinder AJ. Graft failure incidence, risk factors, and outcomes in patients undergoing non-myeloablative allogeneic hematopoietic cell transplantation using post-transplant cyclophosphamide. Transplant Cell Ther. 2024;30:588\u201396.","journal-title":"Transplant Cell Ther"},{"key":"2726_CR55","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1182\/blood.2021011281","volume":"138","author":"M Gooptu","year":"2021","unstructured":"Gooptu M, Romee R, St Martin A, Arora M, Al Malki M, Antin JH, et al. HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. Blood. 2021;138:273\u201382.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02726-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02726-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02726-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T18:02:37Z","timestamp":1768932157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02726-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,18]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2726"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02726-8","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,18]]},"assertion":[{"value":"27 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The scientific boards of the ALWP of the EBMT approved this study. All methods were performed in accordance with the relevant guidelines and regulations. Informed consent was obtained from all subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}